Jubilant Ingrevia reported its Q3 FY26 results, demonstrating resilience amidst persistent pricing pressures. The company sustained its EBITDA margin at 13%, consistent with the previous quarter, and saw revenue increase by 3% for the nine-month period. Strong volume growth, particularly in Specialty Chemicals, helped offset softer pricing. The Board has recommended an interim dividend of ₹2.5 per equity share.
Financial Performance Overview
For Q3 FY26, Jubilant Ingrevia reported a total revenue of ₹1,051 crore. EBITDA stood at ₹136 crore with a margin of 13%. Despite challenges in pricing, strong volume growth across segments helped maintain stable business performance. The company’s financial results were approved on February 4th, 2026.
Segment Highlights
Specialty Chemicals
Segment revenue reached ₹458 crore.EBITDA was ₹116 crore, with a margin of 25%. Continued traction in CDMO customers and volume growth in Pyridine contributed positively. The segment was affected by pricing pressure across core products.
Nutrition & Health Solutions
Segment revenue grew to ₹201 crore, an 11% increase quarter-over-quarter. EBITDA was ₹23 crore, with the margin at 11%. The segment achieved its highest ever B3 volume sales in the last seven quarters.
Chemical Intermediates
Segment revenue totaled ₹393 crore. EBITDA was ₹15 crore, with a margin of 4%. Increased market volumes were seen in India with an uptick in agro and paracetamol. The segment faced continued challenges in Europe.
Strategic Progress
The company made significant strides across its strategic pillars, including customer-centric approaches, operational efficiency, and ESG initiatives. The commissioning of a new boiler at the Bharuch site and the progress on the Agro-Innovator project are key milestones. Jubilant Ingrevia has also expanded its opportunity funnel, reflecting deeper customer engagement.
Source: BSE
